Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sutro Biopharma (STRO) Leases (2021 - 2025)

Sutro Biopharma's Leases history spans 5 years, with the latest figure at $13.3 million for Q3 2025.

  • For Q3 2025, Leases fell 29.88% year-over-year to $13.3 million; the TTM value through Sep 2025 reached $13.3 million, down 29.88%, while the annual FY2024 figure was $17.7 million, 22.52% down from the prior year.
  • Leases for Q3 2025 was $13.3 million at Sutro Biopharma, down from $14.8 million in the prior quarter.
  • Across five years, Leases topped out at $30.1 million in Q3 2021 and bottomed at $13.3 million in Q3 2025.
  • The 5-year median for Leases is $24.0 million (2023), against an average of $22.9 million.
  • The largest annual shift saw Leases dropped 8.95% in 2022 before it decreased 29.88% in 2025.
  • A 5-year view of Leases shows it stood at $29.0 million in 2021, then decreased by 8.95% to $26.4 million in 2022, then decreased by 13.72% to $22.8 million in 2023, then fell by 22.52% to $17.7 million in 2024, then decreased by 24.53% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Leases are $13.3 million (Q3 2025), $14.8 million (Q2 2025), and $16.3 million (Q1 2025).